We examined the occurrence of JAK2V617F and JAK2 exon 12 mutations in a clinical cohort of polycythemia vera (PV) in Taiwan. Of 22 patients with PV, 17 (77%) had the V617F mutation, and all 5 V617F-negative patients (23%) had the exon 12 mutation. We found 3 different exon 12 mutations: 3 N542-E543del, 1 F537-K539delinsL, and 1 novel mutation, I540-E543delinsKK. Patients with V617F showed significantly higher WBC and platelet counts at diagnosis than patients with exon 12 mutations (P = .021 and P = .038, respectively). We report a surprisingly high incidence of exon 12 mutations in Taiwanese patients with PV, a result quite different from reports in the Western literature (P = .001). Our data suggest that exon 12 mutation of JAK2 in patients with PV may have an uneven geographic distribution. A clinical laboratory providing the V617F test alone may risk missing a substantial number of patients with PV in areas with a high incidence of exon 12 mutation. © American Society for Clinical Pathology.
CITATION STYLE
Yeh, Y. M., Chen, Y. L., Cheng, H. Y., Su, W. C., Chow, N. H., Chen, T. Y., & Ho, C. L. (2010). High percentage of JAK2 exon 12 mutation in asian patients with polycythemia vera. American Journal of Clinical Pathology, 134(2), 266–270. https://doi.org/10.1309/AJCPK7KGOWPHYWM0
Mendeley helps you to discover research relevant for your work.